dc.contributor.author | Dal, Mehmet Sinan | |
dc.contributor.author | Ulu, Bahar Uncu | |
dc.contributor.author | Uzay, Ant | |
dc.contributor.author | Akay, Olga Meltem | |
dc.contributor.author | Beşışık, Sevgi | |
dc.contributor.author | Yenerel, Mustafa Nuri | |
dc.contributor.author | Çelik, Serhat | |
dc.contributor.author | Kaynar, Leylagül | |
dc.contributor.author | Yücel, Orhan Kemal | |
dc.contributor.author | Deveci, Burak | |
dc.contributor.author | Sönmez, Mehmet | |
dc.contributor.author | Mehtap, Özgür | |
dc.contributor.author | Beköz, Hüseyin Saffet | |
dc.contributor.author | Sunu, Cenk | |
dc.contributor.author | Salim, Ozan | |
dc.contributor.author | Ulaş, Turgay | |
dc.contributor.author | Kartı, Sami | |
dc.contributor.author | Altuntaş, Fevzi | |
dc.contributor.author | Ferhanoğlu, Burhan | |
dc.contributor.author | Tuğlular, Tülin Fırat | |
dc.date.accessioned | 2023-02-23T12:36:44Z | |
dc.date.available | 2023-02-23T12:36:44Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Dal, M. S., Ulu, B. U., Uzay, A., Akay, O. M., Beşışık, S., Yenerel, M. N. ... Tuğlular, T. F. (2023). Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: A real-world data from Turkey. Annals of Hematology, 102(1), 133-140. https://doi.org/10.1007/s00277-022-05052-x | en_US |
dc.identifier.issn | 0939-5555 | |
dc.identifier.issn | 1432-0584 | |
dc.identifier.uri | https://doi.org/10.1007/s00277-022-05052-x | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/10517 | |
dc.description.abstract | Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.8 mg/kg, rituximab 375 mg/m2 on day 1, and bendamustine 90 mg/m2 on days 1–2 of each cycle. Median age at Pola-BR initiation was 55 (19–84). The overall response rate was 47.9%, including 32.4% CR rate when a median of 3 cycles was applied. With a median follow-up of 5 months, the median OS was 5 months. Grade 3–4 neutropenia and thrombocytopenia were the most common hematological toxicities. The real-world data from our cohort showed the Pola-BR is an effective option with a manageable toxicity profile. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Bendamustine | en_US |
dc.subject | Diffuse Large B-cell Lymphoma | en_US |
dc.subject | Polatuzumab Vedotin | en_US |
dc.subject | Refractory | en_US |
dc.subject | Relapsed | en_US |
dc.subject | Rituximab | en_US |
dc.title | Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: A real-world data from Turkey | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Annals of Hematology | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-2035-9462 | en_US |
dc.authorid | 0000-0003-1237-8281 | en_US |
dc.identifier.volume | 102 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.startpage | 133 | en_US |
dc.identifier.endpage | 140 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1007/s00277-022-05052-x | en_US |
dc.institutionauthor | Kaynar, Leylagül | |
dc.institutionauthor | Beköz, Hüseyin Saffet | |
dc.identifier.wosquality | Q2 | en_US |
dc.identifier.wos | 000885401400002 | en_US |
dc.identifier.scopus | 2-s2.0-85142265282 | en_US |
dc.identifier.pmid | 36401621 | en_US |
dc.identifier.scopusquality | Q1 | en_US |